TL;DR
This week's developments are defined by swift regulatory interventions to contain emerging biological threats and modernize standards of care. The FDA has enacted emergency measures to address a sudden domestic outbreak of the flesh-eating New World screwworm, while also approving landmark, targeted disease-modifying therapies for Type 1 diabetes, prostate cancer, and the first new chemical sunscreen filter in more than two decades. Meanwhile, public health authorities are mobilizing clinical trials in Central Africa as the regional Ebola outbreak continues its rapid escalation.
The Return of Eradicated Parasites and Escalating Epidemics Strain Public Health Budgets
The re-emergence of a long-eradicated parasite in the American Southwest, coupled with the relentless expansion of a rare Ebola strain in Central Africa, is forcing emergency regulatory interventions amidst intense political scrutiny over funding.
In mid-June 2026, the FDA issued an Emergency Use Authorization for generic nitenpyram to treat New World screwworm infestations in pets following the parasite's sudden re-emergence in Texas and New Mexico New World Screwworm Re-emerges in US Southwest+1. This domestic emergency unfolds alongside a worsening international crisis; as reported by the World Health Organization, the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo and Uganda has escalated from the nearly 600 cases tracked last week to 695 cumulative confirmed cases Bundibugyo Ebola Outbreak Exceeds 690 Cases as US and WHO Mobilize Therapeutic Clinical Trials
. According to reporting by Forbes, the screwworm's return has sparked fierce political backlash over recent funding cuts to a joint containment program, while the U.S. government has expanded its international aid by providing a $20 million funding increase to support therapeutic clinical trials in Africa Bundibugyo Ebola Outbreak Exceeds 690 Cases as US and WHO Mobilize Therapeutic Clinical Trials
.
"The Food and Drug Administration has issued an emergency approval for an over-the-counter drug that will allow it to be used to treat dogs and cats for New World Screwworm, a flesh-eating parasite that was largely eradicated from U.S. livestock in the 1960s before reappearing last month after DOGE-led government cuts slashed ongoing efforts to prevent its spread." — New World Screwworm Re-emerges in US Southwest
+1
"Following the recommendations of WHO advisory groups on candidate therapeutics to be considered for a clinical trial, WHO, Africa CDC and other partners are supporting the Democratic Republic of the Congo and Uganda in implementing the clinical trial. This include using MBP134 and REGN3479 for treatment, and using obeldesivir for post-exposure prophylaxis..." — Bundibugyo Ebola Outbreak Exceeds 690 Cases as US and WHO Mobilize Therapeutic Clinical Trials
When political budget cuts disrupt long-standing biological containment programs, the resulting biosecurity gaps can quickly spark domestic agricultural emergencies, while regional disease outbreaks in volatile areas require rapid, coordinated international intervention before they slip entirely out of control.
What to watch: Watch whether the USDA can successfully establish its planned sterile fly production facility in Texas to halt the parasite's spread before it inflicts extensive damage on the U.S. cattle herd.
Targeted Oncology and Immunology Approvals Redefine Standard Care for Chronic Diseases
Federal regulators are opening critical clinical windows for targeted biological therapies, greenlighting treatments that halt disease progression in newly diagnosed diabetic children and genetically defined prostate cancer patients.
In mid-June 2026, the FDA granted accelerated approval to Sanofi's Tzield to delay the decline of pancreatic insulin production in children with newly diagnosed Stage 3 Type 1 diabetes, as detailed in a Sanofi Press Release FDA Grants Accelerated Approval to Sanofi’s Tzield for Newly Diagnosed Stage 3 Type 1 Diabetes. On the same day, according to an AstraZeneca Press Release, the agency approved Truqap in combination with abiraterone and prednisone as the first targeted treatment for adult patients with PTEN-deficient metastatic prostate cancer, demonstrating a 19% reduction in the risk of radiographic disease progression or death FDA Approves AstraZeneca’s Truqap Combination for PTEN-Deficient Metastatic Prostate Cancer
.
"The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in endogenous (own) insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D." — FDA Grants Accelerated Approval to Sanofi’s Tzield for Newly Diagnosed Stage 3 Type 1 Diabetes
"Patients with PTEN-deficient metastatic hormone-sensitive prostate cancer... experience faster progression and worse prognosis than those without PTEN deficiency. Keeping patients with this form of prostate cancer in remission and free from disease progression as long as possible is a high priority." — FDA Approves AstraZeneca’s Truqap Combination for PTEN-Deficient Metastatic Prostate Cancer
Moving disease-modifying therapies into the immediate post-diagnosis "honeymoon" window of Type 1 diabetes and targeting genetically defined subgroups in prostate cancer shifts the treatment paradigm from general symptom management to precision interception.
What to watch: Watch whether Sanofi's Phase 3 BETA-PRESERVE confirmatory trial can verify the clinical benefit required to maintain Tzield's accelerated approval.
Regulatory Modernization Breaks a Decades-Long Stagnation in Consumer Sun Care
A landmark regulatory approval has introduced the first new chemical sunscreen filter to the United States market in over two decades, signaling a shift toward consumer safety and international alignment.
In early June 2026, the FDA approved bemotrizinol as an active ingredient for over-the-counter sunscreens, providing American consumers with a highly photostable, broad-spectrum UV filter that has been used safely in Europe for decades FDA Approves Bemotrizinol as First New Chemical Sunscreen Ingredient in Over 20 Years. According to reporting by CNN, this approval addresses a massive regulatory delay, granting manufacturer DSM-Firmenich exclusive rights to market its proprietary formulation for 18 months before other companies can adopt the ingredient FDA Approves Bemotrizinol as First New Chemical Sunscreen Ingredient in Over 20 Years
.
"Bemotrizinol changes the calculus of sun care. It is highly photostable — meaning it won’t break down when hot summer sun hits your skin — unlike avobenzone, currently the only non-mineral filter in the U.S. that provides meaningful UVA coverage..." — FDA Approves Bemotrizinol as First New Chemical Sunscreen Ingredient in Over 20 Years
By clearing a highly photostable filter that provides robust UVA protection without absorbing into the bloodstream, the FDA is finally addressing a massive safety and efficacy gap that has left American consumers decades behind foreign markets.
What to watch: Watch whether the FDA will continue to leverage the administration's Make America Healthy Again regulatory priorities to fast-track other long-delayed over-the-counter ingredients.
What surprised us
- Internal FDA friction almost derailed Sanofi's Tzield approval. CDER Director Tracy Beth Høeg's disagreement with CDER clinical staff delayed the decision past its original April 21, 2026 goal date, prompting Sanofi to briefly request pulling the drug from the fast-track program before the dispute was resolved FDA Grants Accelerated Approval to Sanofi’s Tzield for Newly Diagnosed Stage 3 Type 1 Diabetes
.
- A flesh-eating parasite eradicated in the 1960s has returned, linked to DOGE budget cuts. The re-emergence of the New World screwworm occurred just days after government cuts slashed funding for a joint monitoring program in Central America, and right as temporary bans on cattle imports from Mexico were lifted without mandated screening New World Screwworm Re-emerges in US Southwest
- U.S. sunscreens deliver, on average, only 24% of the UVA protection implied by their SPF labels. Because the FDA has not approved a new chemical filter in over twenty years, American formulations have been severely deficient in blocking deep-penetrating UVA rays compared to their European counterparts FDA Approves Bemotrizinol as First New Chemical Sunscreen Ingredient in Over 20 Years
.